<DOC>
	<DOC>NCT00278915</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (early puberty) in girls with McCune-Albright syndrome (MAS).</brief_summary>
	<brief_title>Faslodex in McCune Albright Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Puberty, Precocious</mesh_term>
	<mesh_term>Fibrous Dysplasia, Polyostotic</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Females less than or equal to 10 years of age (prior to 11th birthday) Diagnosis of McCuneAlbright syndrome (MAS) Progressive precocious puberty (PPP) associated with MAS Received any prior treatment for PPP associated with MAS with fulvestrant Abnormal platelet count or liver function tests Bleeding disorders Long term anticoagulation therapy Known hypersensitivity to any component of the study drug</criteria>
	<gender>Female</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Progressive Precocious Puberty</keyword>
	<keyword>PPP</keyword>
	<keyword>McCune-Albright Syndrome</keyword>
	<keyword>MAS</keyword>
</DOC>